Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets
1. FDA places Sarepta's LGMD gene therapy trials on clinical hold due to safety concerns. 2. Three patient deaths may be linked to Sarepta's investigational products. 3. Needham downgrades SRPT, fearing potential removal of Elevidys from the market. 4. Analysts are critical of Sarepta's relationship with the FDA and future debt obligations. 5. Market predictions for SRPT price drop significantly across several investment firms.